Clinical diagnosis value of P16 gene methylation and P53 antibody in serum of non-small cell lung cancer patients

Abstract

Objective To investigate the clinical diagnosis value of P16 gene methylation and P53 antibody in serum for non-small cell lung cancer (NSCLC). Methods The P16 gene methylation and P53 antibody level in serum from 98 NSCLC patients and 60 normal controls were tested with methylation-specific polymerase chain reaction and enzyme linked immunosorbent assay. Results The sensitivities of P16 gene methylation and P53 antibody qualitative detection were 70.41% and 58.16% for prediction diagnosis of NSCLC, the specificities were 85.00% and 93.33%, the correct indexes were 0.554 and 0.515.The positive rates of P16 gene methylation in serum of NSCLC patients and healthy controls were 70.41% and 15.00% (χ2=45.709, P<0.001). The positive rates of P53 antibody in serum of NSCLC patients and healthy controls were 58.16% and 6.67% (χ2=41.638, P<0.001). The result of receiver operating characteristic curve in the diagnosis of NSCLC showed that the quantitative detection of serum P53 antibody in the diagnosis of NSCLC was statistically significant.The sensitivity and specificity of combined detection of P16 methylation and P53 antibody were 82.56% and 78.33% for NSCLC diagnosis, the correct index was 0.610.The sensitivity of combined detection of P16 methylation and P53 antibody in NSCLC was higher than that of single detection (χ2=14.105, P=0.001). Conclusions The detection of P16 gene methylation and P53 antibody in serum of NSCLC patients is of practical significance.The sensitivity of combined detection is higher than that of single detection. Key words: P16; Methylation; Protein P53; Antibody; Non-small cell lung cancer; Combined detection